BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36614297)

  • 1. Platinum-Based Regimens Are Active in Advanced Pediatric-Type Rhabdomyosarcoma in Adults and Depending on HMGB1 Expression.
    Hindi N; Carrillo-García J; Blanco-Alcaina E; Renshaw M; Luna P; Durán J; Jiménez N; Sancho P; Ramos R; Moura DS; Martín-Broto J
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG).
    Germà-Lluch JR; Garcia del Muro X; Tabernero JM; Sánchez M; Aparicio J; Alba E; Barnadas A
    Ann Oncol; 1999 Mar; 10(3):289-93. PubMed ID: 10355572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
    Noujaim J; Thway K; Jones RL; Miah A; Khabra K; Langer R; Kasper B; Judson I; Benson C; Kollàr A
    Anticancer Res; 2015 Nov; 35(11):6213-7. PubMed ID: 26504053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA
    J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 7. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
    El Weshi A; Memon M; Raja M; Bazarbashi S; Rahal M; El Foudeh M; Pai C; Allam A; El Hassan I; Ezzat A
    Am J Clin Oncol; 2004 Oct; 27(5):529-34. PubMed ID: 15596925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A report on second neo-plasms in seven children with solid tumors.
    Hu H; Zhang W; Li J; Li F; Li R; Liu Z; Huang D
    Ann Ital Chir; 2022; 92():331-338. PubMed ID: 36052474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
    Winter S; Fasola S; Brisse H; Mosseri V; Orbach D
    Pediatr Blood Cancer; 2015 Nov; 62(11):1935-41. PubMed ID: 26150380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
    Bisogno G; Fuchs J; Dasgupta R; Ferrari A; Haduong JH; Rogers T; Walterhouse DO; Coppadoro B; Xue W; Vokuhl C; Hawkins DS; Seitz G; Merks JHM; Sparber-Sauer M; Venkatramani R
    Cancer; 2022 Dec; 128(23):4150-4156. PubMed ID: 36250420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New combination chemotherapy in refractory rhabdomyosarcoma of the prostate: a case report and review of the literature].
    Takeuchi T; Komeda H; Oguchi K; Ishihara S; Iwata H; Kanematsu M; Kuriyama M; Ban Y; Tanaka T
    Hinyokika Kiyo; 1987 Nov; 33(11):1899-905. PubMed ID: 2451411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
    Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
    J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies and outcomes for spinal rhabdomyosarcoma: A series of 11 cases in a single center and review of the literature.
    Wang T; Gao X; Yang J; Guo W; Wu Z; Tang L; Cao S; Cai X; Liu T; Jia Q; Xiao J
    Clin Neurol Neurosurg; 2020 May; 192():105729. PubMed ID: 32058205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours.
    Anthoney DA; McKean MJ; Roberts JT; Hutcheon AW; Graham J; Jones W; Paul J; Kaye SB
    Br J Cancer; 2004 Feb; 90(3):601-6. PubMed ID: 14760371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
    Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
    J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults.
    Sasada S; Kodaira M; Shimoi T; Shimomura A; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Anticancer Res; 2016 May; 36(5):2429-32. PubMed ID: 27127153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.